Precision Immunotherapy in Axial SpA
Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →What's hot
View all perspectives
What's Hot
PsA: Impact of Sex
Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A Fibroblast Renaissance
Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read more →
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome
Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Say Goodbye to Methotrexate in PMR?
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.
Read more →
Predicting Flares in Rheumatoid Arthritis
Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Read more →
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Sex Differences in Psoriatic Arthritis
Dr. Catherine Bakewell shared key takeaways from a session presented Sunday morning by Dr. Laura Coates and Dr. Lihi Eder, as well as abstract 1709, presented at the 2024 ACR Convergence meeting in Washington, DC. 1709
Watch video →
ICYMI: Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read more →
ICYMI: Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Read more →
ICYMI: Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases.
Read more →
The Psoriatic March: PsA before PsO
Dr. Antoni Chan discusses abstract 2328, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A useful urinary biomarker for lupus nephritis
Dr. Andrea Fava discusses plenary abstract 1642, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Dreaming of Relief: The Importance of Sleep in Lupus and Rheumatoid Arthritis
Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance of addressing sleep disturbances in these conditions.
Read more →
Antoni Chan MD (Prof) synovialjoints
11 months 1 week ago
Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis.
- Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension.
- 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb
sheila RHEUMarampa
11 months 1 week ago
@YooJinKimYJK @andreafava et al: 20% of pts in their #lupus cohort had recurrent pericarditis.
Majority had 1 recurrence (51%)
Independent predictors of recurrence:
Younger age
Prednisone tx
Active dse
Time from initial episode
🔅regular ffup is 🔑
@RheumNow #ACR24 abs2372 https://t.co/UELwE31X0u
Mrinalini Dey DrMiniDey
11 months 1 week ago
➡️More DMARD-exposed pts w late-onset RA reduce long-term GC use than DMARD-unexposed
➡️Persistent GC use is common
➡️In DMARD-exposed, GC use may be related to limited access to high-cost drugs
➡️In DMARD-unexposed, comorbidity burden may limit DMARD use
Ab2606 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey
11 months 1 week ago
How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)?
➡️75 pts with ARDs
💉2-week #MTX discontinuation after each dose of RZV
⏩Significant boost in immune response without difference in flare rates
Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be
Eric Dein ericdeinmd
11 months 1 week ago
A#2649
Relapsing Polychondritis
Latent Class Analysis to define clinical phenotypes of heterogeneous dx
Type 1- ear, nose, subglottic stenosis
2- tracheo/bronchomalacia
3- absence tracheomalacia
Decision tree to classify pts in subgroups
#ACR24 @RheumNow https://t.co/xpZedPVl7f
Richard Conway RichardPAConway
11 months 1 week ago
Loiseau et al. 4700 pSS, 47000 comparators. pSS associated with increased risk of every CV/VTE outcome. Did not have that in my priors! @RheumNow #ACR24 Abstr#2631 https://t.co/QKemUhbcG8 https://t.co/twpjdS2L63
Eric Dein ericdeinmd
11 months 1 week ago
A#2650
MRI can show extent of vessel wall inflamm to guide severity of GCA
Brain & orbital MRI performed
Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10)
33 GCA (17 ocular), 41 not GCA
CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx
@RheumNow #ACR24 https://t.co/19XCuZJXqF
sheila RHEUMarampa
11 months 1 week ago
Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO
Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO
@RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4
Antoni Chan MD (Prof) synovialjoints
11 months 1 week ago
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/JEqVPLGNfu
sheila RHEUMarampa
11 months 1 week ago
Did you know?
#Lupus arthritis have clinical and US classifications.
On MRI, findings will show:
- periarticular hyperplastic tissue
- capsular swelling
- edematous tenosynovitis
@RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/EoKh2Q3V9Z
Richard Conway RichardPAConway
11 months 1 week ago
McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses shown in picture. Good efficacy across domains, but this is phase 2, will await the phase 3. @RheumNow #ACR24 Abstr#2582 https://t.co/FQflZMPes0 https://t.co/DATqo37yib
Eric Dein ericdeinmd
11 months 1 week ago
A#2582 McInnes
Sonelokimab - IL17A,F nanobody
Prior P2 in PsO, HS
ARGO: P2 W24 RCT
Significant improv in ACR response
High PASI90/100 data
Up to 60% achieved MDA by W24
Improved PsAID domains (PRO)
Safety no IBD, MACE, depr. 2% oral candida
IZAR-1,2 - P3 ongoing
#ACR24 @RheumNow https://t.co/O4fEhTC8jK
sheila RHEUMarampa
11 months 1 week ago
SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study.
Reasons for stopping SEC:
lack of efficacy
pt decision
lost to ffup
AEs
Reassuring data on SECs position in the treatment of PsA/AS.
@Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi
Richard Conway RichardPAConway
11 months 1 week ago
Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG
TheDaoIndex KDAO2011
11 months 1 week ago
Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt
Poster Hall